An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
Derrick S Fung, Jess T WhitsonDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Glaucoma is a progressive, neurodegenerative optic nerve disease that can cause significant visual morbidity and affects over 60 million people worldwide. The only kn...
Enregistré dans:
Auteurs principaux: | Fung DS, Whitson JT |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c0dd7ba5f4ad43eaae716b06f10dd0d7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
par: Addis VM, et autres
Publié: (2018) -
Epidemiology and characteristics of childhood glaucoma: results from the Dallas Glaucoma Registry
par: Fung DS, et autres
Publié: (2013) -
Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
par: McCabe CF, et autres
Publié: (2012) -
Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
par: Shiratori N, et autres
Publié: (2021) -
Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
par: Dasso L, et autres
Publié: (2018)